Cannabidiol Medication Intervention Trial (CALM-IT)
Summary
Agitation is common in patients with Alzheimer's Disease (AD) and is one of the most distressing and symptoms of AD. Agitation is associated with faster loss of independent living, increased caregiver stress, poorer quality of life, and increased risk of death. In addition, current treatments show only mild benefits but come with side effects. Therefore, identifying safer and more effective treatments for agitation in AD is a priority.
Eligibility
Eligible ages: 55 to 100
Inclusion criteria:
1. Diagnosis of Alzheimer's disease
2. Significant agitation
3. 55 years or older
4. Availability of a caregiver that can participate along with the participant
Exclusion criteria:
1. Allergies to cannabis and cannabis products.
2. Presence of significant delusions and/or hallucinations.
3. Major depression.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Ramnik Sekhon
Principal investigator:
Zahinoor Ismail
Clinical trial:
Yes
REB-ID:
REB24-0702